Tryp Therapeutics 

Tryp Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing psilocybin-related molecules. The company's Psilocybin-For-Neuropsychiatric Disorders (PFN) program focuses on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. Its program candidate includes TRP-8803, a psilocybin-based drug product for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.